<DOC>
	<DOCNO>NCT01690637</DOCNO>
	<brief_summary>This prospective , randomize , double-blind , placebo-controlled trial conduct tertiary care pediatric hospital El Salvador Panama . The primary purpose study determine whether empiric oseltamivir phosphate treatment give time hospital admission child less 10 year age hospitalize influenza effectively reduce illness severity . Additional objective : 1 ) evaluate tolerability oseltamivir phosphate treatment , 2 ) evaluate effect oseltamivir treatment viral clearance development oseltamivir-resistant influenza virus treatment child hospitalize influenza , 3 ) estimate direct indirect cost all-cause respiratory illness influenza-associated respiratory illness require hospitalization , 4 ) evaluate effect empiric oseltamivir treatment influenza season cost . The primary study hypothesis child laboratory-confirmed influenza receive empiric oseltamivir phosphate treatment initiated time hospital admission short duration hospitalization shorter time resolution sign severe respiratory illness compare child receive placebo . The secondary study hypotheses child laboratory-confirmed influenza receive oseltamivir phosphate treatment reduction time non-detectable influenza virus influenza viral RNA child all-cause respiratory illness receive oseltamivir phosphate likely experience severe adverse event child receive placebo .</brief_summary>
	<brief_title>Panama El Salvador Children 's Oseltamivir Study</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Age &lt; 10 year Accompanied parent guardian capacity grant sign write informed consent consent enrollment Has respiratory illness define modify IMCI criterion pneumonia : Cough sore throat AND Fast breathing , define respiratory rate 60 breath per minute great child 0 &lt; 2 month , OR respiratory rate 50 breath per minute great child 2 &lt; 12 month , OR respiratory rate 40 breath per minute great child 12 &lt; 60 month , OR respiratory rate 30 breath per minute great child 59 year Planned hospital admission Symptom onset 7 day time study screen day 1 day symptom onset Concomitant severe vomit illness prior enrollment would preclude ability take medication orally define 3 vomit episode precede 24 hour Prematurity ( birth less 37 week gestation ) child age less 3 month Birth weight less 2500 gram child age less 3 month Chronic supplemental oxygen requirement home Known history renal dysfunction History gastrointestinal resection result gastrointestinal abnormality might hinder absorption oral medication ( shortgut syndrome ) History previous serious adverse reaction oseltamivir phosphate Receipt oseltamivir phosphate 5 day prior presentation admit hospital Previous enrollment study hospitalization end less 14 day prior current admission</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Oseltamivir</keyword>
	<keyword>Tamiflu</keyword>
</DOC>